licensing Archives -

Lantheus on POINT in radio-oncology with $2bn licensing deal

Phil Taylor Lantheus, licensing, Oncology, partnering, POINT Biopharma, radiopharmaceuticals 0 Comment

Lantheus’ pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two

Lantheus on POINT in radio-oncology with $2bn licensing deal

https://pharmaphorum.com/news/lantheus-on-point-in-radio-oncology-with-2bn-licensing-deal/

News/ News/ R&D

Novo Nordisk grabs NASH drug from Ventus in $703m deal

Phil Taylor hepatology, Immunology and inflammation, licensing, NASH, NLRP3, Novo Nordisk, Ventus Therapeutics 0 Comment

Denmark’s Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus

Novo Nordisk grabs NASH drug from Ventus in $703m deal

https://pharmaphorum.com/news/novo-nordisk-grabs-nash-drug-from-ventus-in-703m-deal/

News/ News/ R&D

Almirall joins IL-2 push in autoimmunity with $507m Simcere deal

Phil Taylor Almirall, autoimmune disease, cytokine therapies, dermatology, licensing, Simcere Pharmaceutical 0 Comment

Almirall has licensed an interleukin-2 (IL-2) drug from China’s Simcere Pharma, joining the ranks of companies looking at

Almirall joins IL-2 push in autoimmunity with $507m Simcere deal

https://pharmaphorum.com/news/almirall-joins-il-2-push-in-autoimmunity-with-507m-simcere-deal/

News/ News/ R&D

Lava fires up a $700m cancer licensing deal with Seagen

Phil Taylor immuno-oncology, Lava Therapeutics, licensing, Oncology, partnering, Seagen 0 Comment

While a rumoured takeover by Merck & Co has yet to materialise, Seagen is getting on with its

Lava fires up a $700m cancer licensing deal with Seagen

https://pharmaphorum.com/news/lava-fires-up-a-700m-cancer-licensing-deal-with-seagen/

Helping to support momentum on antimicrobial innovation

News/ News/ R&D

Undeterred by FDA setback, GSK snaps up Spero antibiotic

Phil Taylor antibiotic, antimicrobial resistance, fda, GSK, licensing, regulatory, Spero Therapeutics, tebipenem 0 Comment

GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by

Undeterred by FDA setback, GSK snaps up Spero antibiotic

https://pharmaphorum.com/news/undeterred-by-fda-setback-gsk-snaps-up-spero-antibiotic/

News/ News/ News/ Oncology/ R&D

Takeda farms out cancer drug alisertib to Puma Biotech

Phil Taylor alisertib, breast cancer, licensing, lung cancer, Oncology, Puma Biotechnology, Takeda 0 Comment

Takeda has decided that there is a future for its aurora kinase A inhibitor alisertib after it failed

Takeda farms out cancer drug alisertib to Puma Biotech

https://pharmaphorum.com/news/takeda-farms-out-cancer-drug-alisertib-to-puma-biotech/

News/ News/ News/ Oncology/ Sales and Marketing

On heels of new data, Gilead pays $455m for Asian Trodelvy rights

Phil Taylor Asia-Pacific, breast cancer, China, Everest Medicines, Gilead Sciences, licensing, Trodelvy 0 Comment

On the same day as it reported encouraging new data for its cancer drug Trodelvy, Gilead Sciences has

On heels of new data, Gilead pays $455m for Asian Trodelvy rights

https://pharmaphorum.com/news/on-heels-of-new-data-gilead-pays-455m-for-asian-trodelvy-rights/

News/ News/ R&D

Merck swings back into Alzheimer’s with $1.1bn Cerevance alliance

Phil Taylor Alzheimer's disease, Cerevance, licensing, Merck & Co, neurology, partnering 0 Comment

Merck & Co’s earlier efforts to find new therapies for Alzheimer’s disease resulted in failure, but the company

Merck swings back into Alzheimer’s with $1.1bn Cerevance alliance

https://pharmaphorum.com/news/merck-swings-back-into-alzheimers-with-1-1bn-cerevance-alliance/

News/ News/ News/ Oncology/ Sales and Marketing

Sobi bolsters blood division via $435m ADC licensing deal

Phil Taylor ADC Therapeutics, licensing, loncastuximab tesirine, non-Hodgkin lymphoma, Oncology, SOBI, Zynlonta 0 Comment

Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics’ lymphoma therapy

Sobi bolsters blood division via $435m ADC licensing deal

https://pharmaphorum.com/news/sobi-bolsters-blood-division-via-435m-adc-licensing-deal/

Trending

licensing

Login